Similar Search Results

Hospital Reimbursement Price Cap for Cancer Drugs: the French experience in controlling hospital drug expenditures

Degrassat-Théas, Albane; Bensadon, M.; Rieu, C.; … - Université Paris-Dauphine (Paris IX) - 2012

price cap. Hospitals still negotiate with pharmaceutical firms, who set their prices freely, and then charge the national … in costs per diagnostic-related group and secondly to avoid an uncontrolled increase of prices due to a lack of interest … index representing the ratio of the purchase prices to the RT was built from 2004 to 2007 in order to make a 'before …

Persistent link: https://www.econbiz.de/10010706947

Temporary Authorization for Use: Does the French Patient Access Programme for Unlicensed Medicines Impact Market Access After Formal Licensing?

Degrassat-Théas, Albane; Paubel, Pascal; Parent de … - Université Paris-Dauphine (Paris IX) - 2013

Background To reach the French market, a new drug requires a marketing authorization (MA) and price and reimbursement agreements. These hurdles could delay access to new and promising drugs. Since 1992, French law authorizes the use of unlicensed drugs on an exceptional and temporary basis...

Persistent link: https://www.econbiz.de/10010707774

Assurance-maladie, accès aux soins et redistribution des revenus

Le Pen, Claude - Université Paris-Dauphine (Paris IX) - 2002

We develop a "welfarist" model in which the collective demand for health insurance is mainly explained by a solvability motive : health insurance does not have for principal function to treat the risk aversion of solvent agents but to make it possible to individuals who are too poor to assume...

Persistent link: https://www.econbiz.de/10010708942